FDA REBUFFS CONCERNS FOR GENERIC FLONASE

APRIL 01, 2006

In approving the first generic version of GlaxoSmithKline's allergy drug Flonase, FDA officials rejected bioequivalence concerns raised in several citizen petitions that questioned the approval criteria for that drug. After considering the issues raised by those petitioners, FDA officials stressed that generic drug applications are subject to "the same thorough and rigorously scientific review for safety, effectiveness, and quality as the applications for new (branded) drugs."

According to the FDA, "consumers and health professionals can be assured that an approved generic drug is bioequivalent to a brand name drug and is its equal in dosage form, strength, route of administration, quality, performance characteristics, and intended use." The generic version, known as fluticasone propionate nasal spray, is being manufactured by Roxane Laboratories.




SHARE THIS SHARE THIS
0

Become A RESPIMAT T.O.P. Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?


Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.